Home Featured Page 17

Featured

Latest

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic Care Has the Field Asking, and What To Do About It

The Psychedelic Writers Guild’s Denver Mixer

The Mushroom Cure – Special Live Filming

Pα+ Psychedelic Bulletin #222: Unpacking EPIsoDE; Meta-Analysis Says Psychedelics No Better...

BREAKING: Otsuka to Acquire Methylone Drug Developer Transcend in $1.23B Deal

Esme Dark – Psychedelics, Somatics and the Shadow

What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and...

Film Club: Music for Mushrooms

Psychedelic Approvals on Track, Advocacy in Flux: A Washington Dispatch on...

Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research,...

Gov. Spencer Cox Signs Utah’s H.B. 390 Into Law, Authorizing Psychedelic...

EDITOR PICKS

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic Care Has the Field Asking, and What To Do About It

The Psychedelic Writers Guild’s Denver Mixer

The Mushroom Cure – Special Live Filming

Pα+ Psychedelic Bulletin #222: Unpacking EPIsoDE; Meta-Analysis Says Psychedelics No Better...

BREAKING: Otsuka to Acquire Methylone Drug Developer Transcend in $1.23B Deal

Esme Dark – Psychedelics, Somatics and the Shadow

What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and...

Film Club: Music for Mushrooms

Psychedelic Approvals on Track, Advocacy in Flux: A Washington Dispatch on...

Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research,...

Gov. Spencer Cox Signs Utah’s H.B. 390 Into Law, Authorizing Psychedelic...

EDITOR PICKS

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY